Radiosensitizers with Hyperfractionation in Radiotherapy

The use of misonidazole in radiotherapy for the treatment of cancer confronts the therapist with the problem of choosing how to relate the administration schedules of the drug with the radiation schedule (1). He must decide whether it is advisable to keep the usual dose-fraction schedules — for which tolerance is well known -or whether these schedules can be changed in order to exploit in the best way possible the radiosensitizing effect of this drug on the hypoxic cells present in tumours.